Online Only Articles

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands
Department of Hematology, Academic Medical Center (AMC), Amsterdam, the Netherlands
HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands
Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands
Department of Hematology, University Medical Center (UMCG), Groninge, the Netherlands
Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands
Department of Hematology, Meander Medical Center, Amersfoort, the Netherlands
Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands
HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands
Working group on Hemato-Oncologic Genome Diagnostics (WHGD), Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
Department of Hematology, University Hospital, Maastricht, the Netherlands
Department of Hematology, HAGA Hospital, the Hague, the Netherlands
Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands
Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands
Vol. 101 No. 4 (2016): April, 2016 https://doi.org/10.3324/haematol.2015.132431